Gilead's Kevin Young appointed Commander of the British Empire
This article was originally published in Scrip
Kevin Young, Gilead's executive vice-president of commercial operations, has been appointed a Commander of The British Empire in recognition of his "services to the healthcare and pharmaceutical industries, particularly to the development and marketing of life-changing medicines." The civilian honour comes after 28 years in the biotech and pharmaceutical sector. He joined Gilead in 2004 after working at companies including Amgen and AstraZeneca.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.